Crx-5TD

**Crx-5TD** is a preclinical **small molecule** anti-infective program from **Cryptyx Biosciences** being developed for **melioidosis caused by Burkholderia pseudomallei**. Publicly available company pipeline information describes it as a natural product-derived candidate discovered through Cryptyx's platform and characterizes it as having a **new target and mode of action**, with reported **greater specificity and potency than trimethoprim sulfamethoxazole** and an asserted lack of effect on **commensal bacteria**. No specific molecular target, chemical name, dosage form, route of administration, or manufacturer has been publicly disclosed.